Avita Medical Analyst Coverage Initiated by Zacks


NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 19, 2013) - Regenerative medicine Company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) is pleased to announce that Zacks Investment Research, Inc (zacks.com), based in Chicago, IL, USA, has initiated coverage.

The news release and abbreviated report can be found on Yahoo Finance. The full initiation report can be viewed on the Avita Medical website.

Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue‐culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell® Spray‐On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE‐marked for Europe, TGA‐registered in Australia, and SFDA‐cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.


Avita Medical Ltd.
Sharoni Billik
Investor Relations
Phone:+1 818 827-1675
Email: sbillik@avitamedical.com
View Comments (0)